Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI): Seattle, Washington, USA - February 13-16, 2017

S. A. Rizza, W. El Atrouni, R. Bhatia, Z. Temesgen

Research output: Contribution to journalArticle

Abstract

The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) convened scientists, clinicians, and policy makers from around the world to share and discuss important developments in HIV infection and related diseases. Highlights of this year's CROI include advances in HIV prevention, clinical trials of established and novel antiretroviral agents, and strategies for HIV cure.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalDrugs of the Future
Volume42
Issue number4
DOIs
StatePublished - Apr 2017

Keywords

  • Bictegravir
  • Cabotegravir
  • Dapivirine
  • Doravirine
  • Elsulfavirine
  • GS-986
  • Ibalizumab
  • MK-8591
  • PRO-140
  • Romidepsin
  • UB-421
  • Vesatolimod

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI): Seattle, Washington, USA - February 13-16, 2017'. Together they form a unique fingerprint.

  • Cite this